Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivabradine - Servier

Drug Profile

Ivabradine - Servier

Alternative Names: AMG-998; Coralan; Coraxan; Corlanor; Corlentor; Ivabradine hydrochloride; LANCORA; ONO-1162; Procoralan; S-16257; S-16257-2; S-57

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Developer Amgen; Ono Pharmaceutical; Servier; University of California, San Diego
  • Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Hyperpolarisation activated cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Chronic heart failure
  • Phase III Coronary artery disease; Tachycardia
  • Phase II Low cardiac output

Most Recent Events

  • 08 Aug 2022 Ono Pharmaceutical completed a phase-III clinical trial in Chronic heart failure in Japan (PO) (JapicCTI-153007)
  • 29 Jun 2021 Dana-Farber Cancer Institute and Amgen terminates a phase II trial in Chronic heart failure in USA (PO) as funding terminated (NCT03137537)
  • 06 Apr 2021 Dana-Farber Cancer Institute and Amgen suspends a phase II trial in Chronic heart failure in USA (PO) as funding terminated (NCT03137537)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top